Ligand Pharmaceuticals (LGND) Operating Income Growth (3y) (2013 - 2026)

Ligand Pharmaceuticals (LGND) Operating Income Growth (3y) (2013 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - 16.96%
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 38.78%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 13.47%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -12.10%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn 69.02%
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Ligand Pharmaceuticals 5.92 Bn 5.14 Bn 48.45 Mn 6.93%

Historic Data

Download Data
DateValue
Mar 31, 2026 6.93%
Dec 31, 2025 39.05%
Sep 30, 2025 64.50%
Jun 30, 2025 -0.85%
Mar 31, 2025 -166.74%
Dec 31, 2024 -31.15%
Sep 30, 2024 -41.51%
Jun 30, 2024 -34.21%
Mar 31, 2024 -14.11%
Dec 31, 2023 -29.00%
Sep 30, 2023 -6.35%
Jun 30, 2023 -31.60%
Mar 31, 2023 55.36%
Dec 31, 2022 -25.46%
Sep 30, 2022 63.77%
Jun 30, 2022 60.02%
Mar 31, 2022 -86.28%
Dec 31, 2021 4.37%
Sep 30, 2021 -12.40%
Jun 30, 2021 -13.30%